	US 12,459,979 B2
	Modified chimeric antigen receptors and methods of use
Stuart A. Sievers, Van Nuys, CA (US); and Jed J. w. Wiltzius, Winchester, MA (US)
Assigned to Kite Pharma, Inc., Santa Monica, CA (US)
Filed by Kite Pharma, Inc., Santa Monica, CA (US)
Filed on Jun. 23, 2022, as Appl. No. 17/847,597.
Application 17/847,597 is a division of application No. 16/192,492, filed on Nov. 15, 2018, granted, now 11,390,655.
Claims priority of provisional application 62/587,336, filed on Nov. 16, 2017.
Prior Publication US 2023/0039418 A1, Feb. 9, 2023
Int. Cl. A61K 40/31 (2025.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 15/62 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 14/4748 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4205 (2025.01); A61K 40/4215 (2025.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/2878 (2013.01); C12N 15/62 (2013.01); A61K 2239/21 (2023.05); C07K 2317/31 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2319/03 (2013.01); C07K 2319/75 (2013.01); C07K 2319/91 (2013.01); C12N 5/0638 (2013.01)]

6 Claims

1. A vector encoding a polypeptide comprising a chimeric antigen receptor (CAR), wherein the CAR comprises:

(i) an antibody or antigen-binding domain selected from the group consisting of a single chain fragment (scFv), an affibody, a Fab fragment, a F(ab′)2 fragment, and a disulfide-linked Fv (sdFv);

(ii) a transmembrane domain comprising the amino acid sequence of EITLIIFGVMAIVIGTILLISYGI (SEQ ID NO:69) or LTSIISAVVVILLVVVLGVVFGILIK (SEQ ID NO: 70); and

(iii) an intracellular domain.